Effect of dendritic cell-cytokine induced killer cells in patients with triple-negative breast cancer
详细信息 查看官网全文
- 英文论文题名：Effect of dendritic cell-cytokine induced killer cells in patients with triple-negative breast cancer
- 论文作者：Xie Yunqing ; Liu Jian ; Lin Xiaowei ; Liu Shijia ; Ying Mingang ; Zheng Qiuhong
- 英文论文作者：Xie Yunqing ; Liu Jian ; Lin Xiaowei ; Liu Shijia ; Ying Mingang ; Zheng Qiuhong ; Fujian Provincial Key Laboratory of Tumor Biotherapy
- 年：2016
- 作者机构：Fujian Provincial Key Laboratory of Tumor Biotherapy;
- 英文论文关键词：dendritic cells ; cytokine-induced killer cells ; adjuvant immunotherapy ; triple-negative breast cancer
- 会议召开时间：2016-11-04
- 会议录名称：第十一届全国免疫学学术大会摘要汇编
- 英文会议录名称：Abstracts of 2016 CSI Congress on Immunology
- 语种：英文
- 分类号：R737.9
- 学会代码：IGMD
- 会议名称：第十一届全国免疫学学术大会
- 会议地点：中国安徽合肥
- 主办单位：中国免疫学会
- 学会名称：中国免疫学会
- 页数：1
- 文件大小：1291k
- 原文格式：D
- 会议级别：全国
摘要
Purpose: Triple-negative breast cancer(TNBC) is a breast cancer type with poor prognosis due to the absence of targets for the treatment of endocrine and anti-HER-2 therapy. Furthermore, only about 20% of TNBC are sensitive to conventional chemotherapy. Therefore, this study aimed to evaluate the clinical efficacy of adjuvant dendrtic cell(DC)-cytokineinduced killer cells(CIK) immunotherapy combined with chemotherapy with/without radiotherapy in patients with postoperative TNBC.Method: From December 1,2006 to February28,2011, 68 patients with postoperative TNBC were included in this retrospective study: 43 cases received chemotherapy with/without radiotherapy; 25 cases received DC-CIK cells infusion combined with chemotherapy with/without radiotherapy.Results: Survival analysis showed the 5-years disease-free survival(DFS) rate was significantly higher in the DC-CIK group compared with the non- DC-CIK group(P=0.049). Further subgroup analysis stratified according to tumor–node–metastasis(TNM) stages showed that the 5-years DFS was significantly increased in DC-CIK group with advanced TNM stages(including IIb,III,IV TNM stage) than the non- DC-CIK, and 5-year OS rate in advanced-stage subgroup was also improved although it only approved borderline statistical significance(P=0.051).Conclusions: Our results demonstrated that TNBC patients with advanced TNM stages could benefitted from adjuvant DC-CIK cells infusion combined with conventional therapy in terms of preventing disease relapse and increasing overall survival.
Purpose: Triple-negative breast cancer(TNBC) is a breast cancer type with poor prognosis due to the absence of targets for the treatment of endocrine and anti-HER-2 therapy. Furthermore, only about 20% of TNBC are sensitive to conventional chemotherapy. Therefore, this study aimed to evaluate the clinical efficacy of adjuvant dendrtic cell(DC)-cytokineinduced killer cells(CIK) immunotherapy combined with chemotherapy with/without radiotherapy in patients with postoperative TNBC.Method: From December 1,2006 to February28,2011, 68 patients with postoperative TNBC were included in this retrospective study: 43 cases received chemotherapy with/without radiotherapy; 25 cases received DC-CIK cells infusion combined with chemotherapy with/without radiotherapy.Results: Survival analysis showed the 5-years disease-free survival(DFS) rate was significantly higher in the DC-CIK group compared with the non- DC-CIK group(P=0.049). Further subgroup analysis stratified according to tumor–node–metastasis(TNM) stages showed that the 5-years DFS was significantly increased in DC-CIK group with advanced TNM stages(including IIb,III,IV TNM stage) than the non- DC-CIK, and 5-year OS rate in advanced-stage subgroup was also improved although it only approved borderline statistical significance(P=0.051).Conclusions: Our results demonstrated that TNBC patients with advanced TNM stages could benefitted from adjuvant DC-CIK cells infusion combined with conventional therapy in terms of preventing disease relapse and increasing overall survival.
Purpose: Triple-negative breast cancer(TNBC) is a breast cancer type with poor prognosis due to the absence of targets for the treatment of endocrine and anti-HER-2 therapy. Furthermore, only about 20% of TNBC are sensitive to conventional chemotherapy. Therefore, this study aimed to evaluate the clinical efficacy of adjuvant dendrtic cell(DC)-cytokineinduced killer cells(CIK) immunotherapy combined with chemotherapy with/without radiotherapy in patients with postoperative TNBC.Method: From December 1,2006 to February28,2011, 68 patients with postoperative TNBC were included in this retrospective study: 43 cases received chemotherapy with/without radiotherapy; 25 cases received DC-CIK cells infusion combined with chemotherapy with/without radiotherapy.Results: Survival analysis showed the 5-years disease-free survival(DFS) rate was significantly higher in the DC-CIK group compared with the non- DC-CIK group(P=0.049). Further subgroup analysis stratified according to tumor–node–metastasis(TNM) stages showed that the 5-years DFS was significantly increased in DC-CIK group with advanced TNM stages(including IIb,III,IV TNM stage) than the non- DC-CIK, and 5-year OS rate in advanced-stage subgroup was also improved although it only approved borderline statistical significance(P=0.051).Conclusions: Our results demonstrated that TNBC patients with advanced TNM stages could benefitted from adjuvant DC-CIK cells infusion combined with conventional therapy in terms of preventing disease relapse and increasing overall survival.
引文